Galapagos NV (GLPG) Given Average Rating of “Buy” by Analysts
Shares of Galapagos NV (NASDAQ:GLPG) have been given a consensus recommendation of “Buy” by the nine analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $102.50.
Several research analysts have weighed in on GLPG shares. Zacks Investment Research raised Galapagos NV from a “hold” rating to a “buy” rating and set a $90.00 price objective on the stock in a research report on Wednesday, March 22nd. Instinet started coverage on Galapagos NV in a research report on Wednesday, March 1st. They issued a “buy” rating and a $87.00 price objective on the stock. Nomura started coverage on Galapagos NV in a research report on Wednesday, March 1st. They issued a “buy” rating on the stock. Cowen and Company reissued a “buy” rating on shares of Galapagos NV in a research report on Wednesday, June 21st. Finally, BTIG Research reissued a “buy” rating and issued a $98.00 price objective on shares of Galapagos NV in a research report on Tuesday, June 20th.
A number of hedge funds and other institutional investors have recently bought and sold shares of GLPG. Tower Research Capital LLC TRC acquired a new position in Galapagos NV during the first quarter valued at $161,000. Bank of Montreal Can boosted its position in Galapagos NV by 8,736.4% in the first quarter. Bank of Montreal Can now owns 1,944 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 1,922 shares in the last quarter. Cim Investment Mangement Inc. acquired a new position in Galapagos NV during the first quarter valued at $203,000. Karp Capital Management Corp acquired a new position in Galapagos NV during the first quarter valued at $206,000. Finally, Airain ltd acquired a new position in Galapagos NV during the first quarter valued at $237,000. 19.94% of the stock is currently owned by institutional investors and hedge funds.
Shares of Galapagos NV (NASDAQ GLPG) traded down 1.68% during midday trading on Tuesday, reaching $75.08. The company’s stock had a trading volume of 158,608 shares. The stock has a market cap of $3.47 billion, a PE ratio of 728.93 and a beta of 1.77. Galapagos NV has a one year low of $49.43 and a one year high of $94.88. The firm has a 50-day moving average of $83.52 and a 200-day moving average of $75.77.
About Galapagos NV
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.